ModifiedCignaPolicy N/A

Coverage criteria for brand drugs when a bioequivalent generic is available

Defines medical necessity criteria for coverage of brand-name drugs when a bioequivalent generic exists for Cigna-administered health benefit plans; affects prescribers and payers determining prior authorization and coverage.

Policy Summary

PayerCigna

PolicyCoverage criteria for brand drugs when a bioequivalent generic is available

Policy CodePolicy N/A

Change TypeProducts added/removedrevised criteria and plan applicability

Effective Date

Next Review Date

Key ActionPrescriber must document that the patient tried the bioequivalent generic and cannot take it due to inactive ingredient differences causing significant allergy or serious adverse reaction.

SourceLink

POLICY UPDATE CHANGES

Removed diagnosis requirement from several anticonvulsant products and expanded medical necessity review to Employer and Individual and Family Plans for multiple products.

Added numerous products to support medical necessity review for Employer Plans and/or Individual and Family Plans (examples include Myrbetriq, Ancobon, Vytorin, Zetia, and many others across revision entries).

Removed specific products (e.g., Taytulla, Moviprep, Suprep, Daliresp, Lopressor) in various revision entries.

~300+brand-to-generic pairs listed

12 monthsdefault approval duration

NCexplicit applicable state

manyproducts added/removed

Coverage Criteria for Brand Drugs with Bioequivalent Generics

Medical necessity for brand when generic available

Covered when ALL of the following are met

Primary criteria: (1) A brand drug listed in the policy has a bioequivalent generic available; AND (2) The patient has tried the bioequivalent generic product; AND (3) The patient cannot take the bioequivalent generic due to a formulation difference in inactive ingredient(s) (for example, differences in dyes, fillers, preservatives) which, per the prescriber, would result in a significant allergy or serious adverse reaction.

All products are approved for a duration of 12 months unless otherwise noted.

Medical necessity for brands with bioequivalent generics

Covered when ALL of the following are met

brand-with-bioequivalent: The brand product has a bioequivalent generic listed in the table

See listed brand/generic pairs in chunks 18-19

Policy Summary

PayerCigna

PolicyCoverage criteria for brand drugs when a bioequivalent generic is available

Policy CodePolicy N/A

Change TypeProducts added/removedrevised criteria and plan applicability

Effective Date

Next Review Date

Key ActionPrescriber must document that the patient tried the bioequivalent generic and cannot take it due to inactive ingredient differences causing significant allergy or serious adverse reaction.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

clinical-appropriateness: Dosage, frequency, duration of therapy, and site of care are reasonable, clinically appropriate, and supported by evidence-based literature; adjusted based on severity, alternative treatments, and prior response.

Clinical documentation expected; receipt of samples does not satisfy criteria

Any exception to the coverage criteria other than a documented significant allergy or serious adverse reaction to an inactive ingredient is considered not medically necessary. The policy requires prescriber documentation that the patient tried the bioequivalent generic and cannot take it because of a formulation difference in inactive ingredients (for example, dyes, fillers, preservatives) that would, per the prescriber, result in a significant allergy or serious adverse reaction. All approvals default to 12 months unless otherwise noted.

Receipt of a sample product does not satisfy any criteria requirements for coverage. Coverage determinations require documented clinical evidence as specified in the policy (including trial and intolerance to the bioequivalent generic where applicable); possession or use of a sample alone is insufficient to meet those requirements.

Requests for a brand-name product when a bioequivalent generic is available are considered not medically necessary unless ALL specified conditions are documented: (1) the patient has tried the bioequivalent generic; and (2) the patient cannot take the generic due to a formulation difference in inactive ingredient(s) that, according to the prescriber, would cause a significant allergy or serious adverse reaction. Documentation of these conditions is required for prior authorization and coverage.

Coding, Approval Duration, and Listed Products

Listed brand-to-bioequivalent genericsmixedCovered

Veltin	Bioequivalent Generic = clindamycin/tretinoin 1.2%-0.025% gel
Vesicare	Bioequivalent Generic = solifenacin tablets
Vigamox 0.5% solution	Bioequivalent Generic = moxifloxacin 0.5% solution
Viibryd	Bioequivalent Generic = vilazodone
Vimpat	Bioequivalent Generic = lacosamide
Vitatrue	Bioequivalent Generic = prenatal vitamin, iron 30 mg/folic acid 1.4 mg/DHA 300 mg
Vivelle-DOT	Bioequivalent Generic = estradiol transdermal patch
Vytorin	Bioequivalent Generic = ezetimibe/simvastatin tablets
Wellbutrin SR	Bioequivalent Generic = bupropion hydrochloride extended-release tablet
Wellbutrin XL	Bioequivalent Generic = bupropion extended release

1–10 of 29

1/3

inv-08: Approval duration

Default approval durationAll products are approved for a duration of 12 months unless otherwise noted.

ApplicabilityApplies to brand products with bioequivalent generics listed in the policy when medical necessity criteria are met.

Renewal/reauthorization expectationApprovals may be renewed subject to continued documentation of medical necessity and clinical appropriateness.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for brand products when a bioequivalent generic exists unless the prescriber documents that the patient tried the bioequivalent generic and cannot take it due to a formulation difference in inactive ingredient(s) that would cause a significant allergy or serious adverse reaction. Coverage approvals are generally for up to 12 months unless otherwise noted.

Prior authorization required when a bioequivalent generic is available; exception only with required clinical justification.
Approvals default to a 12-month duration unless specified otherwise.

Note

Medical Necessity Review / Prior Authorization Applicability

Medical necessity review and prior authorization applicability: requests for brand products listed as having bioequivalent generics will be subject to medical necessity review. Recent policy revisions expand or remove diagnosis requirements and adjust which products are subject to review for Employer Plans and Individual and Family Plans — verify plan type and applicable effective dates when submitting requests.

Policy applies to Employer Plans and Individual and Family Plans as indicated by revision history; check effective dates in policy header and revision notes.
Some products had diagnosis requirements removed and were added to medical necessity review for specific plan types per revision history.

Denial Risk

Coding-Based Denial Risk

Claims submitted without appropriate covered diagnosis or procedure codes listed under the applicable Coverage Policy will be denied as not covered. When billing, providers must use the most appropriate codes as of the effective date of the submission.

Claims lacking covered codes under the applicable Coverage Policy = denial risk.
Use the most appropriate and current codes at time of submission.

Documentation Required

Required Clinical Justification

Required clinical justification: the prescriber must document that the patient has tried the bioequivalent generic product and cannot take it due to a formulation difference in inactive ingredient(s) (for example, differences in dyes, fillers, preservatives) that would, per the prescriber, result in a significant allergy or serious adverse reaction. Any other exception to step therapy is considered not medically necessary.

Prescriber statement that generic was tried and caused or would cause significant allergy or serious adverse reaction due to inactive ingredient differences.
Receipt of sample product does not satisfy criteria requirements.

Billing Rule

Coding and Claims Documentation

Coding and claims documentation: submission must include the covered diagnosis and/or procedure codes that support medical necessity and the most appropriate codes as of the submission date. Clinical documentation should also support dosage, frequency, duration of therapy, and site of care as reasonable and evidence-supported.

Include covered diagnosis/procedure codes that align with the Coverage Policy.
Provide clinical notes documenting dosage, frequency, duration, and site of care and rationale for brand over generic.
Failure to provide appropriate codes or clinical documentation may result in denial.

Initial Coverage Conditions

Initial coverage

Initial coverage condition for listed brands with generics

Initial therapy: Patient has tried the bioequivalent generic and cannot tolerate it due to inactive ingredient formulation differences causing a significant allergy or serious adverse reaction as documented by the prescriber.

Approvals generally for 12 months.

Step Therapy Requirements

Step	Requirement	Notes
1
Patient must have tried the bioequivalent generic product prior to coverage of the brand
Inability to take the generic must be due to a formulation difference in inactive ingredient(s) (e.g., dyes, fillers, preservatives) that the prescriber documents would result in a significant allergy or serious adverse reaction; approvals generally for 12 months unless otherwise noted.

Site of Care and Clinical Appropriateness

Documentation Required

Ensure dosage/frequency/duration and site are clinically appropriate

Dosage, frequency, duration, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature; approvals are generally for 12 months unless otherwise noted.

Documentation Required

Document and justify site of care

Site of care must be reasonable and clinically appropriate and supported by evidence-based literature.

Definitions

inv-20: FDA generic equivalence

FDA generic equivalence — core definitionGeneric medications contain the same active/key ingredient, have the same strength, use the same dosage form, and use the same route of administration as the brand-name drug.

Performance and reviewFDA review ensures generics perform the same way in the human body and have the same intended use as the name brand medication.

Quality standardsAll FDA-approved generic drugs meet the same standards for quality, strength, purity, and stability as brand-name drugs; FDA inspects manufacturing, packaging, and testing sites.

inv-21: Multi-sourced brand drug

DefinitionA multi-sourced brand drug is a brand-name drug marketed or sold by two or more manufacturers or labelers, is no longer protected under patent exclusivity, and has a therapeutically equivalent generic available.

Implication for coverageWhen a brand is multi-sourced and therapeutically equivalent generics exist, the policy requires trial of the bioequivalent generic prior to brand coverage unless documented intolerance to inactive ingredients is provided.

Market statusIndicates absence of patent exclusivity and availability of generic competition from multiple manufacturers.

Background and Regulatory Basis

The policy aligns with FDA standards for generic drug equivalence: a generic contains the same active ingredient, strength, dosage form, and route of administration as the brand-name drug and is reviewed by the FDA for equivalence. Because bioequivalent generics are expected to perform similarly to their brand counterparts, coverage is limited to brand products only when there is prescriber-documented inability to tolerate the generic due to inactive ingredient differences.